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Background: Prevalence rates for Restless Legs Syndrome (RLS) and risk of Obstructive 
Sleep Apnea (OSA) in individuals with Neuromyelitis Optica Spectrum Disorder (NMOSD) 
and Clinically Isolated Syndrome (CIS) are unknown. The aims of the present study were to 
assess symptoms of RLS and self-assessed risks of OSA in individuals with NMOSD and 
CIS, to compare these prevalence rates with those of persons with multiple sclerosis (MS), 
and to associate RLS and OSA with EDSS scores and daytime sleepiness, fatigue, 
paresthesia, and medication. 
Methods: A total of 495 individuals (mean age = 34.92 years, 84.9% females) were assessed. 
Of these, 24 had NMOSD, 112 had CIS and 359 had MS. Trained neurologists ascertained 
individuals’ neurological diagnoses, assessed their EDSS scores, and conducted a clinical 
interview to assess RLS. Additionally, participants completed questionnaires covering 
sociodemographic information, risks of snoring and obstructive sleep apnea, daytime 
sleepiness, fatigue, paresthesia and medication. 
Results: Prevalence rates of RLS were 45.8% in NMOSD, 41.1% in CIS, and 28.7% in MS. 
Prevalence rates of self-assessed risks of OSA were 8.3% in NMOSD, 7.7% in CIS, and 
7.8% in MS; these rates were not significantly different. Across the entire sample and within 
the diagnostic groups, RLS and OSA scores were unrelated to EDSS, daytime sleepiness, 
fatigue or medication. 
Conclusions: Individuals with NMOSD, CIS and MS have high prevalence rates for RLS and 
self-assessed risks of OSAs, which are unrelated to EDSS, daytime sleepiness, fatigue, 
paresthesia, or medication. Sleep issues should be monitored during routine check-ups for 
individuals with NMOSD and CIS. 
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 Research indicates that mental and somatic issues are associated with impaired sleep. 
As regards neurological diseases, sleep disturbance is one of the first responses to chronic 
inflammatory diseases [1-3], and reduced sleep quality together with daytime sleepiness are 
associated with adverse consequences for quality of life[1]. 
In the present study, we focused on the prevalence rates for Restless Legs Syndrome 
(RLS) and self-assessed risks of Obstructive Sleep Apnea (OSA) in individuals with 
Neuromyelitis Optica Spectrum Disorder (NMOSD) and Clinically Isolated Syndrome (CIS), 
as compared to persons suffering from multiple sclerosis (MS). While MS sufferers report 
higher rates of RLS and OSAs than healthy controls [4-15], we do not have the equivalent 
prevalence rates for individuals with NMOSD or CIS.  
Restless Legs Syndrome is a clinically diagnosed neurological disorder. Symptoms 
are unpleasant sensations in the legs, the worsening of these sensations during rest, relief 
when moving, and exacerbation of the sensations in the evening [16] The prevalence rate of 
RLS in the general population is about 4.2% [16]. For MS sufferers, prevalence rates appear 
to vary according to the type of MS. Whereas some studies [17] have reported higher RLS 
prevalence rates among individuals with primary progressive MS, and lower RLS prevalence 
rates among individuals with relapsing-remitting MS (RRMS), Douay et al. [18] reported 
higher RLS prevalence rates among individuals with relapsing-remitting MS. Vavrova et al. 
[19], however, reported higher RLS prevalence rates among individuals with secondary 
progressive MS (SPMS). We therefore assessed the MS prevalence rates separately for 
RRMS and SPMS. 
Obstructive Sleep Apnea (OSA) is a sleep disorder resulting from the reduction or 
complete cessation of breathing [20-22]. In most cases OSA is peripherical; that is to say the 
upper airways are mechanically obstructed, resulting in a decrease in O2-saturation which in 
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turn produces an O2-CO2-inbalance and consequently re-arousal of the resting organism. 
While Braley et al. [21, 23] estimated that up to 21% of individuals with MS suffer from 
OSAs, to our knowledge the corresponding rates for individuals with either CIS or NMOSD 
are not known. OSAs are associated with a broad range of cardio-vascular and health-related 
diseases [24]. Knowledge of the prevalence rates for OSA among individuals with NMOSD, 
CIS, and MS might therefore help to prevent other health-related problems. Accordingly, in 
the present study participants self-assessed the risks of obstructive sleep apnea.  
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic inflammatory 
disease characterized by the involvement of the optic nerve, the spinal cord and the brain 
[25]. Formerly, NMOSD was considered a variant of Multiple Sclerosis. [26]. However, 
although NMOSD and MS have similar clinical features, they have different pathological and 
immunological pathways [27]. The antibody against aquaporin4 (anti-AQP4) in the central 
nervous system plays an important role in the pathogenesis of NMOSD, and this feature 
allows us clinically to distinguish NMOSD from MS [27, 28]. Moreover, the majority of 
individuals with NMOSD experience both a relapsing course of illness and severe symptoms, 
either of which may lead to severe disability, along with a reduced health-related quality of 
life (HRQOL). Barzegar et al. (2018, 2019) were able to showed that, compared to 
individuals with MS, individuals with NMOSD had lower scores for health-related quality of 
life, along with higher scores for depression and sleep disturbances. However, to our 
knowledge the prevalence rates for RLS and OSAs in individuals with NMOSD, have yet to 
be determined. 
Clinically Isolated Syndrome (CIS) has been described by Armoiry et al. [29] as 
isolated events of symptomatic neurological disturbance which last more than 24 hours and 
which are considered the first signs of clinical demyelination of the central nervous system. 
Additionally, the brief description provided by Armoiry et al. [29] indicates that the clinical 
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syndromes are usually mono-focal but sometimes also multi-focal. Armoiry et al. [29] also 
stressed that people with CIS are at increased risk of developing MS, but without being 
formally diagnosed with MS [30]. Langer-Gould et al. [31] also noted that there were no 
reliable prevalence rates for CIS but that in a large sample of individuals with neurological 
diseases the incidence of CIS varied between 2.4% and 6.8% depending on ethnicity and 
gender. 
As regards sleep in individuals with CIS, to our knowledge only one study has 
assessed prevalence rates in this group. Gonzales-Platas et al.[32] conducted an observational 
study in the territory of Northern Tenerife and assessed 240 individuals with demyelinating 
disease, including 163 individuals with MS, 36 with clinically isolated syndrome (CIS), 26 
with radiological isolated syndrome (RIS), and 15 with other demyelinating diseases (DD). 
Individuals completed a series of self-rating questionnaires covering subjective sleep, 
daytime sleepiness, Restless Leg Syndrome, Obstructive Sleep Apnea, fatigue, and quality of 
life. Results showed that compared to those with CIS, RIS and DD, individuals with MS 
reported more issues of insomnia, while for all other dimensions (RLS, OSAs, daytime 
sleepiness), no significant differences were observed between the groups. In brief, as regards 
sleep in individuals with CIS, only one study has examined this and shown that the 
prevalence rates of RLS and OSAs were comparable to prevalence rates for individuals with 
MS.  
 Next, there is some evidence that the occurrence of RLS can be associated with higher 
EDSS scores [17, 19, 33-35]. In the current study we therefore examined whether higher RLS 
scores were associated with higher EDSS scores.  
 Last, there are conflicting findings as regards the association between RLS and 
daytime sleepiness. While some studies have reported an association between higher RLS 
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scores and daytime sleepiness [17] others have not [33, 36, 37]. The present study has the 
potential to resolve this uncertainty one way or the other.  
 The following three exploratory research questions were formulated. 
First, we asked about the prevalence rates for RLS and self-assessed risks of OSA in 
individuals with NMOSD and CIS, as compared to MS sufferers. Second, we explored the 
associations between RLS, self-assessed risks of OSAs, and EDSS scores, daytime 
sleepiness, fatigue and paresthesia, both across the sample as a whole and within the 
subsamples of diseases. Third, we asked about participants’ medication and its possible 




Individuals diagnosed with NMOSD, CIS or MS (RRMS; SPMS) were approached at 
the Isfahan University of Medical Sciences, Isfahan Neurosciences Research Center, Alzahra 
Research Institute, Isfahan (Iran), and asked to participate at the present study on sleep in 
individuals with neurological and neurodegenerative diseases. Eligible individuals were fully 
informed about the aims of the study and the anonymous data handling. Afterwards, 
individuals signed a written informed consent. Trained neurologists assessed EDSS scores, 
clinical psychologists performed a thorough clinical, psychiatric and sleep-related interview, 
and the individuals themselves completed a booklet of questionnaires covering 
sociodemographic and sleep-related matters. The ethical committee of the Isfahan University 
of Medical Sciences (IUMS; Isfahan, Iran) approved the study, which was performed in 




 A total of 506 individuals with NMOSD, CIS or MS (RRMS; SPMS) were 
approached. Of these, 495 completed the study; eleven withdrew from participation or felt 
unable to comply with the study conditions. Inclusion criteria were: 1) age between 18 and 75 
years; 2) diagnose of NMOSD, CIS or MS, as ascertained by a trained neurologist; 3) willing 
and able to comply with the study conditions (following the clinical interview; completing 
self-rating questionnaires); 4) signed written informed consent. Exclusion criteria were: 1) 
current comorbid psychiatric disorder such as substance use disorder, mood disorders 
(current manic or depressive episode); 2) acute suicidality; 3) currently unable to answer to a 
clinical interview and to complete self-rating questionnaires.  
 
2.3. Tools 
2.3.1. Expanded Disability Status Scale (EDSS) 
 Trained neurologists assessed individuals’ degree of disability with the EDSS [38] 
The EDSS is an accepted and widely used tool for objective assessment of the disability 
levels of individuals with MS, CIS or NMOSD. The total score is on a scale from 0 to 10, 
with increments of 0.5–1.0, and with higher scores reflecting higher levels of disability. 
EDSS steps 1.0–4.5 refer to people with MS who are fully ambulatory. EDSS steps 5.0–9.5 
are defined by impairment to ambulation. Meyer-Moock et al. [39] reported in their 
systematic review the high validity and reliability of the EDSS. Meyer-Moock et al. [39] also 
concluded that the EDSS is suitable for describing clinical status and degree of physical 
disability, and for monitoring disease progression. 
 
2.3.2. Restless Legs Syndrome  
To diagnose Restless Legs Syndrome, experienced neurologist employed the Restless 
Legs Syndrome – Diagnostic Index (RLS-DI [40]). The following five mandatory questions 
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must be answered with “yes, sometimes experienced in one to four days of a week” (= one 
point), or with “yes, regularly experienced in more than five days of a week” (= two points). 
Question one: “Feel the urge to move legs (and arms)?” 
Question two: “When feeling the urge to move legs (arms), then paresthesia of tension, pain, 
tingling, stinging?” 
Question three: “Do urge to move legs (arms) and feeling of paresthesia begin or worsen 
when being at rest (sitting; lying) or when not moving at all?” 
Question four: “Urge to move or paresthesia do partially or fully disappear when moving 
(walking; stretching)?” 
Question five: “Urge to move or paresthesia are more prominent in the evening and night, 
when compared to daytime?” 
Restless Legs Syndrome was objectively diagnosed, when the sum score was 5 points or 
higher.  
Besides the RLS-DI, also the International Restless Legs Study Group (IRLSSG) rating scale 
[16] was employed in a face-to-face interview following the procedure as set out by the 
International RLS Study group [41]. Questions focus on RLS-related severity such as RLS 
discomfort in legs and arms, need to move around for relief from RLS symptoms, and 
frequency of RLS symptoms. Answers are given on 5-point Likert scales ranging from 0 
(none) to 4 (very severe), with higher scores therefore reflecting more marked symptoms of 
RLS (Cronbach’s α = 0.91). In addition, a categorical variable (no RLS or mild RLS: 0-10 
points; moderate RLS: 11-20 points; severe RLS: 21-30 points; very severe RLS: 31-40 
points) was derived. 
  
2.3.4. Self-assessed risks of Snoring and sleep apnea; Obstructive Sleep Apnea 
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 To self-assess risks of snoring and sleep apnea, two self-rating tools were employed, 
the STOP-Bang [42] and the Berlin questionnaire [43]. 
 
2.3.4.1. STOP-Bang Questionnaire 
The STOP-Bang questionnaire [42] is a self-report, forced-choice (yes/no) scale to 
rate the risks of suffering from obstructive sleep apnea. The questionnaire consists of four 
questions related to snoring (S), tiredness during the daytime (T), observed apneas (O) and 
high blood pressure (P; STOP). When two or more questions are answered with yes then the 
person has a higher risk for obstructive sleep apnea/hypopnea syndrome. The “Bang” portion 
is evaluated by assessing BMI >35 kg/m2 (B), age (>50 years) (A), neck circumference (>40 
cm) (N), and gender (male) (G). One point is assigned for each positive answer and zero for 
each negative answer. High risk for the Obstructive Sleep Apnea/Hypopnea Syndrome 
(OSAHS) on the STOP-Bang is indicated when three or more of the eight questions are 
answered yes. The total score was treated as both a continuous variable a dichotomous 
variable (low risk vs. high risk). The STOP-Bang is a sensitive, reliable screening tool for 
OSA, frequently used in outpatient sleep clinics. 
 
2.3.4.2. Berlin Questionnaire 
 Similar to the STOP-Bang, the Berlin Questionnaire (BQ) [43] is a questionnaire 
designed to self-assess the risks of suffering from Obstructive Sleep Apnea/Hypopnea 
Syndrome (OSAHS). The items are as follows: Category 1: 1. “Do you snore?” (yes/no/I 
don’t know); 2. “Your snoring is…” (as loud as normal breathing/as loud as talking/louder 
than talking); 3. “How often do you snore?” (almost every day/3-4 times the week/1-2 times 
the week/1-2 times the months/rarely or never). 4. Has your snoring ever bothered other 
people?” (yes/no/I don’t know); 5. Has anyone noticed that you stop breathing during sleep?” 
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(almost every day/3-4 times the week/1-2 times the week/1-2 times the months/rarely or 
never). Category 2: 6. “How often do you feel tired or fatigued after your sleep?” (almost 
every day/3-4 times the week/1-2 times the week/1-2 times the months/rarely or never). 7. 
“During your waking time, do you feel tired, fatigued or not up to par?” (almost every day/3-
4 times the week/1-2 times the week/1-2 times the months/rarely or never). 8. “Have you ever 
nodded off or fallen asleep while driving a vehicle?” (yes/no). If your answer is ‘yes’; 9. How 
often does it occur? (almost every day/3-4 times the week/1-2 times the week/1-2 times the 
months/rarely or never). Category 3: 10. “Do you have high blood pressure?” (yes/no/I don’t 
know). High risk for Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS) is defined 
when there are persistent symptoms (more than three or four times per week) in categories 1 
and 2, and hypertension (P140/90 mmHg or use of medication) or BMI P30 kg/m2 in 
category 3. Categories 1 and 2 are positive when the sum of all items is ≥ 2. Individuals are 
classified as having high risk for OSAHS if scores are positive in two or more categories. 
Individuals scoring positive in only one or none of the categories are classified as low risk. 
The sum score was treated as a continuous variable, while a dichotomous variable (low risk 
vs. high risk) was also calculated. 
 
2.3.5. Daytime sleepiness (Epworth Sleepiness Scale; ESS)  
 The Epworth Sleepiness Scale [44] was employed to assess daytime sleepiness. This 
self-rating questionnaire consists of ten items rating the odds of dozing off in different 
activities. Answers are given on 4-point rating scales (0-3), with higher sum scores reflecting 
higher daytime sleepiness. The score can range from 0 to 30 points; a global score greater 
than 10 indicates excessive daytime sleepiness. ESS scores were treated as continuous and as 




Participants completed the Fatigue Severity Scale (FSS; [46]) The FSS consists of 
nine items, and answers are given on 7-point rating scales ranging from 1 (not at all) to 7 
(definitively/almost always), with higher scores reflecting higher levels of fatigue.  
 
2.3.7. Paresthesia 
Patients rated their degree of paresthesia on a 10-point visual analogue scale ranging 
from 0 (no sensations at all) to 10 (severe sensations) [47]. 
 
2.3.8. Medication  
Participants were asked to bring their packages of NMOSD-, CIS-, or MS-related 
medications to the interviews so that the types of medication they were taking could be 
thoroughly assessed.  Medical records provided an additional source of information about 
medications prescribed.  
Medications were clustered into five groups: 1. Interferons such as Avonex or Rebif; 
2.Glatiramer Acetate: Glatinamers; 3. Fumarates and immune suppressives 4. Monoclonal 
antibodies such natalizumab, rituximab; 5; others/unknown/missing. 
 
2.3.9. Body Mass Index (BMI) 
 Individuals’ height and weight were measured during the assessment.  
 
2.4. Statistical analysis 
A series of ANOVAs examined mean differences between individuals with NMOSD, 
CIS, and MS (RRMS; SPMS) with respect to age, EDSS scores, RLS scores, daytime 
sleepiness (ESS) scores, OSAs (StopBang; Berlin), fatigue, and BMI. Post-hoc analyses were 
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performed with Bonferroni-Holm corrections for p-values. With a series of X2-tests, 
differences in prevalence rates for dichotomous dimensions of RLS scores, OSA scores and 
daytime sleepiness (ESS) were calculated between individuals with MS (RRMS; SPMS), CIS 
and NMOSD.  
Pearson’s correlations were computed between age, EDSS score, RLS scores, OSA 
scores, fatigue, and daytime sleepiness (ESS), both for the sample as a whole and separately 
for individuals with MS, CIS and NMOSD. Correlations of r < .29 were considered as small, 
r = .30 to .49 were considered as medium, and r ≥ .50 were considered as large.[48] 
Distributions of types of medication within and between the four groups of 
individuals (NMOSD; CIS; MS: RRMS; SPMS) were calculated using a X2-test.  
With a series of one-way ANOVAs it was determined whether age, EDSS, RLS, 
OSAs, daytime sleepiness, fatigue or paresthesia differed significantly between types of 
medication.  
 Finally, two-way ANOVAs were computed with the factors Medication (interferons; 
Glatiramer acetate; fumarates and immune suppressive; monoclonal antibodies) and Disease 
(NMOSD; CIS; MS: RRMS; SPMS) and the dependent variables age, EDSS, RLS, OSAs, 
daytime sleepiness, fatigue and paresthesia.  
The nominal level of significance was set at alpha < .05. All statistical computations 
were performed with SPSS® 25 (IBM Corporation, Armonk NY, USA) for Apple® Mac®.  
 
3. Results 
3.1. Sample characteristics 
 A total of 495 individuals completed the study. Of these, 420 (84.9%) were female, 
and 75 (15.1%) were male. A total of 24 (4.8%) had NMOSD, 112 (22.5%) had CIS, and 359 
(72,6%) had MS (RRMS: 309 (62,2%); SPMS: 50 (10.1%)). Gender ratio did not differ 
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significantly between the three groups: NMOSD (f: 22; m: 2); CIS (f: 99; m: 13); MS (f: 299; 
m: 60): X2(N = 495, df = 2) = 2.57, p = .28.  
 
3.2. Age, EDSS scores, Restless Legs Syndrome scores, self-assessed risks of Obstructive 
Sleep Apnea scores, daytime sleepiness (ESS), fatigue and paresthesia between individuals 
with NMOSD, CIS and MS.  
   =================== 
   Table 1 about here 
   =================== 
 
Table 1 reports the descriptive and inferential statistical indices for age, EDSS scores, 
daytime sleepiness (ESS), fatigue, paresthesia, self-assessed risks of Obstructive Sleep Apnea 
scores (StopBang; Berlin), separately for individuals with NMOSD, CIS, and MS (RRMS; 
SPMS). Statistical indices are fully reported in the Tables and are not repeated in the text.  
Age differed significantly between individuals with MS, CIS and NMOSD. Post-hoc 
analyses with Bonferroni-Holm corrections for p-values showed individuals with MS were 
older than those with either CIS or NMOSD. Descriptively, individuals with CIS were older 
than those with NMOSD.  
EDSS scores differed significantly between individuals with MS, CIS and NMOSD. 
Post-hoc analyses with Bonferroni-Holm corrections for p-values showed higher EDSS 
scores in individuals with SPMS than those with RRMS, CIS or NMOSD. Descriptively, 
individuals with NMOSD had higher EDSS scores than those with CIS. 
Restless Legs Syndrome scores differed significantly between individuals with MS, 
CIS and NMOSD. Post-hoc analyses with Bonferroni-Holm corrections for p-values showed 
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higher RLS scores in individuals with SPMS and RRMS than those with CIS. There were no 
differences between individuals with CIS and NMOSD.  
Self-assessed risks of Obstructive Sleep Apnea scores (StopBang; Berliner) differed 
significantly between individuals with MS, CIS and NMOSD. Post-hoc analyses with 
Bonferroni-Holm corrections for p-values showed higher OSA scores in individuals with 
SPMS than those with either CIS or RRMS. There were no differences between individuals 
with either CIS or NMOSD.  
As regards daytime sleepiness (ESS), no significant or descriptive mean differences 
were observed between individuals with MS, CIS, and NMOSD. 
For fatigue, individuals with NMOSD had significantly lower scores than those with 
SPMS. 
Paresthesia scores did not differ across the four groups. 
 
3.3. Categories of RLS, self-assessed risks of OSA (StopBang; Berlin) and daytime 
sleepiness, separately for individuals with NMOSD, CIS and MS. 
 
 RLS scores, self-assessed risks of OSA scores and daytime sleepiness (ESS) scores 
were split into categorical variables. Table 2 reports the frequency, distribution and statistical 
calculations for these categorical variables between individuals with NMOSD, CIS and MS.   
 
   =================== 
   Table 2 about here 
   =================== 
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Individuals with CIS had lower moderate RLS scores that expected. Individuals with 
SPMS had higher moderate RLS scores that expected. Individuals with RRMS had more 
severe RLS scores that expected.  
 As regards OSAs, depending on the tool used for assessment, significant differences 
in the prevalence rates of OSAs either were (Stop-Bang) or were not observed (Berlin) 
between individuals with MS, CIS and NMOSD  
 As regards daytime sleepiness (ESS), no significant differences in the prevalence 
rates of daytime sleepiness were observed between individuals with MS, CIS and NMOSD. 
 To summarize, compared to individuals with CIS and NMOSD, occurrence of RLS 
was significantly higher in individuals with MS (SPMS), while no differences were observed 
between the three categories as regards OSAs (depending on the assessment tool) or daytime 
sleepiness.  
 
3.4. Correlations between age, EDSS, RLS, daytime sleepiness (ESS), fatigue, paresthesia, 
and self-assessed risks of Obstructive Sleep Apnea (Stop-Bang; Berlin) 
 
 Table 3 summarizes the correlations between age, EDSS, RLS, dimensions of self-
assessed risks of Obstructive Sleep Apnea (Stop-Bang; Berlin), daytime sleepiness (ESS), 
fatigue, and paresthesia for the entire sample (N = 495).  
 Greater age was significantly associated with higher EDSS, RLS, daytime sleepiness 
and self-assessed risks of Obstructive Sleep Apnea, though the correlation coefficients were 
small. Age was not associated with fatigue or paresthesia. 
 A higher EDSS score was associated with higher RLS, and self-assessed risks of 
Obstructive Sleep Apnea, though again correlation coefficients were small. EDSS was not 
associated with daytime sleepiness, fatigue or paresthesia. 
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 Higher RLS scores were associated with higher fatigue, and self-assessed risks of 
Obstructive Sleep Apnea scores, but correlation coefficients were small. 
 Higher daytime sleepiness was associated with higher self-assessed risks of 
Obstructive Sleep Apnea scores, but the correlation coefficient was small.  
 A higher Fatigue score was associated with higher paresthesia scores. 
 
   =================== 
   Table 3 about here 
   =================== 
 
When correlational computations were performed separately for individuals with NMOSD, 
CIS and MS, the pattern of results remained basically similar (Table 4). 
NMOSD: Higher age was associated with higher EDSS, RLS, OSA and daytime 
sleepiness cores. A higher EDSS score was associated with higher RLS and OSA scores. 
Higher RLS scores were associated with higher fatigue and OSA scores. Daytime sleepiness 
was associated with RLS and OSA scores. Fatigue and paresthesia were associated. All 
correlation coefficients were small. 
CIS: Higher age was associated with higher OSA scores. Higher EDSS scores were 
associated with higher RLS scores. A higher daytime sleepiness was associated with higher 
OSA scores. Fatigue and paresthesia were associated. All correlation coefficients were small. 
 MS: RRMS: Higher age was associated with higher EDSS scores, daytime sleepiness, 
and higher OSA scores (Stop-Bang). A higher EDSS score was associated with higher RLS 
scores. Higher RLS scores were associated with higher paresthesia and OSA scores. Daytime 
sleepiness was related to lower paresthesia scores, but unrelated to the EDSS, RLS and OSA 
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scores. Higher fatigue scores were related to higher OSAs (Berlin) and paresthesia scores. All 
correlation coefficients were small. 
 MS: SPMS: Higher age was associated with higher RLS and OSA scores. Higher 
RLS scores were associated with higher fatigue, paresthesia and OSAs. Fatigue and 
paresthesia were associated. 
   
  
 
   =================== 
   Table 4 about here 
   =================== 
 
3.5. Medication 
 Table 5 reports the groups of medications for individuals with NMOSD, CIS and MS. 
Types of medications (interferons; glatiramer acetate; fumarates and immune suppressiva; 
monoclonal antibodies) and amount of medication did not significantly differ between 
individuals with NMOSD, CIS and MS (X2(N = 495, df = 12) = 12.88, p = .38). 
 
   =================== 
   Table 5 about here 
   =================== 
A series of one-way ANOVAs with Medication as independent factor and age, EDSS, RLS; 
OSAs, daytime sleepiness, fatigue, and paresthesia, confirmed that none of the dependent 
variables differed significantly between types of medication (all F’s < 1.7, p’s > .14). In 
addition, a series of two-way ANOVAs with the factors Medication and Disease, and with 
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age, EDSS, RLS; OSAs, daytime sleepiness, fatigue, and paresthesia as dependent variables 
showed no differences (all F’s < 1.4, p’s > .20). 
 
4. Discussion 
 The key findings of the present study were that in a large sample of individuals 
diagnosed with either Neuromyelitis Optica Spectrum Disorder (NMOSD), Clinically 
Isolated Syndrome (CIS), or Multiple Sclerosis (MS), prevalence rates for Restless Legs 
Syndrome (RLS) and self-rated risks of Obstructive Sleep Apnea (OSA) were high. More 
specifically, individuals with MS (and particularly those with SPMS) had lower prevalence 
rates for RLS than individuals with CIS or NMOSD. However, prevalence rates for self-rated 
risks of OSA did not differ between individuals with NMOSD, CIS and MS, nor were such 
prevalence rates associated with EDSS or daytime sleepiness scores. Medication type was 
unrelated either to the nature of the illness or to the dimensions of age, EDSS, RLS, OSAs, 
daytime sleepiness, fatigue, and paresthesia. The present study adds to the current literature 
in an important way as to our knowledge this is the first study to report and to compare 
prevalence rates for sleep-related issues of individuals with NMOSD, CIS or MS, and to 
relate these rates to medication  and to other psychological dimensions. 
 Three research questions were formulated, and each of these is considered in turn. 
Our first research question concerned the prevalence rates of RLS and self-rated risks 
of OSA in individuals with NMOSD and CIS, compared to those with MS. We found that 
individuals with secondary progressive MS had the lowest prevalence rates for RLS, higher 
than those with NMOSD, CIS or RRMS.  
Prevalence rates for RLS between individuals with NMOSD and CIS did not differ.  
As regards self-assessed risks of OSAs, again, prevalence rates between individuals 
with NMOSD and CIS did not differ, while those with MS had higher prevalence rates (Table 
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2). Table 2 also shows that prevalence rates of self-assessed risks of OSAs differed as a 
function of the assessment tool; it follows that assessing OSAs subjectively via self-rating 
tools carries a risk of imprecision. This points to the desirability of assessing  OSAs, 
including snoring, using objective tools [24]. 
Our second research question concerned the associations between RLS, OSAs, and 
EDSS scores, daytime sleepiness, fatigue and paresthesia, both across the sample as a whole 
and within the subsamples of diseases (Tables 3 and 4). It turned out that higher EDSS scores 
were associated with higher RLS and self-assessed risks of OSA scores; this pattern was 
particularly pronounced in individuals with NMOSD (Table 4). As a general observation, the 
present patterns of results are consistent with previous findings for MS sufferers [17, 19, 33, 
35]. However, the present results expand upon previous work in demonstrating this 
association in individuals with NMOSD and CIS.  
We also found significant correlations between symptoms of RLS, fatigue and 
paresthesia (entire sample and in MS sufferers). This points to a difficulty in separating the 
symptoms of RLS, fatigue and paresthesia, suggesting they may have a common basis in 
tactile misperception.  
Our third research question addressed participants’ medication and its possible 
association with prevalence rates for RLS, and self-assessed risks of OSA. We found disease-
related medications to be unrelated to either RLS or self-assessed risks of OSA. Furthermore, 
as shown in Table 5, types of medications were not related to the nature of the illness, and 
statistical indices show that type of medication was not related in any systematic way to 
scores for RLS, OSAs, EDSS, daytime sleepiness, age, fatigue, or paresthesia. This pattern of 
results needs to be replicated and should for the present be treated with caution, in particular 
due to the high frequency of “missings”, though we believe that the influence of MS-, CIS- 
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and NMOSD-related medication should not be overestimated when investigating sleep, 
daytime sleepiness, fatigue and paresthesia in individuals with these disorders.  
The evidence provided by this study does not allow a deeper understanding as to why 
prevalence rates of RLS and self-assessed risks of OSAs were higher in all groups of disease 
than in the general population. That is to say, we can offer no conclusions as to the 
neurophysiological mechanisms underlying the higher prevalence rates of RLS and OSA that 
we observed.  
As regards RLS, Sieminski et al. [49] appear to present the most comprehensive 
neuronal account of the high overlap between RLS and MS. Briefly, inflammatory processes 
as observed in individuals with MS may lead to an up-regulation of cytokines (Il-6, TNF-
𝛼𝛼) and nitric oxide. Increased cytokines lead to an intra-cellular retention of iron, which in 
turn is the cause of the destruction of the cell and of iron deficiency in other areas of the 
brain. The unbalanced stores of iron leads to a downregulation of dopamine and of 
myelination. A decrease in myelination appears to be causally linked to the development of 
RLS. At the same time, the upregulation of nitric oxide suppresses the expression of myelin 
proteins, which ultimately results in demyelination and symptoms of both RLS and MS.  
As regards a neurological explanation for the high prevalence rate of OSA in 
individuals with MS, first of all Kaminska [50] proposed that Obstructive Sleep Apnea might 
negatively impact on symptoms of MS via increased fatigue. Roelcke et al. [51] showed a 
reduction in cerebral glucose metabolism, and Inglese et al. [52] observed a hypoperfusion of 
specific gray matter regions, always in individuals with MS. Importantly, OSA also causes 
gray matter abnormalities and these could be exacerbated in typical MS-related changes. 
Next, [53] showed that OSA and systemic inflammations increase, leading to the possibility 
that OSA might cause systemic inflammations, which are also typical in individuals with MS. 
Last, Ferini-Strambi et al. [54] and Auer et al. [55] proposed that, in MS, demyelinating 
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lesions may occur in the brain stem, and particularly in the reticulospinal pathways which 
regulate motor control of the upper regulatory tract and which may be impaired leading to not 
peripheral but to central OSA.  
To the best of our knowledge, no theoretical or neurophysiological account has yet 
been offered for the occurrence of RLS and OSA among individuals with CIS and NMOSD. 
However, given their pathophysiological similarities to MS, we suggest that mechanisms 
similar to those described above for individuals with MS might also be applicable for 
individuals with CIS and NMOSD.  
Despite the novelty of the findings, several limitations warn against 
overgeneralization of the present findings. First, it would have been helpful to know the 
impact of RLS and self-assessed risks of OSAs on individuals’ subjective sleep quality. 
Future studies might therefore include, for example, the Pittsburgh Sleep Quality Index [56] 
or the Insomnia Severity Index [57] to assess individuals’ subjective feelings of sleep quality 
and restoring sleep. Second numerous studies have shown that restoring sleep is associated 
with regular physical activity. In this respect, Sadeghi Bahmani et al. (2019a,b) have reported 
positive effects of regular physical activity on objective and subjective sleep patterns in 
female patients with MS. To our knowledge there is no equivalent evidence for individuals 
with CIS and NMOSD. Third, RLS [58] and OSAs [59] are associated with higher rates of 
depression and anxiety. It is therefore possible that latent and unassessed dimensions such as 
depression, or anxiety, might have biased two or more dimensions in the same or opposite 
direction. Fourth, the immobilization test [60] or L-dopa test [61] would have provided a 
more reliable diagnosis of RLS. However, such tests are demanding in terms of cost, 
procedure and laboratory staff. Furthermore, so far as we know these tests have not yet been 
employed to assess RLS in samples as large as in the present study. Fifth, a longitudinal or 
interventional study design would have allowed observation of changes and stability in sleep 
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and disease over time. Sixth, identifying the location of lesion and the burden of such lesions 
might have changed the entire pattern of results.  
 
5. Conclusions 
 The present pattern of results suggests that individuals with NMOSD, CIS and MS are 
at high risk of suffering from RLS and self-assessed risks of OSAs. Sleep disturbances, 
however, were unrelated to EDSS scores, fatigue, or daytime sleepiness. The results are 
clinically relevant, as it is possible that sleep disturbances will remain undetected in 
individuals with NMOSD and CIS. 
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